Conference Coverage

Decision model shows prophylactic double mastectomy more costly to patients


 

AT THE ACS CLINICAL CONGRESS

References

Finally, reconstruction rates were varied to see whether this would impact outcomes. The national reconstruction rate following unilateral mastectomy is about 28%, which resulted in a lifetime cost in the initial analysis model of about $13,703.

In order to make CPM less expensive than UM, the reconstruction rate following CPM would have to be dropped to 0% ($12,580) from the national rate of 75% ($19,286), he said. Further, even if the UM reconstruction rate was hiked to 100%, the lifetime costs associated with a unilateral mastectomy were cheaper at $19,275.

Limitations of the model include the subjective nature of QALYs, the cost-effectiveness analysis is a theoretical model, and its costs need to be validated against real-world numbers, Mr. Keskey said.

During a discussion of the study, however, an attendee expressed concern that the data will be used to deny insurance coverage for women seeking a prophylactic contralateral mastectomy.

The decision to undergo prophylactic mastectomy is very personal and needs to be individualized, despite the suggestion of increased cost and less quality of life in the study, according to senior author and colleague Dr. Nicolas Ajkay.

“For some patients, the thought of repeating breast cancer treatment, though a low probability, may be unacceptable; for others, imaging surveillance may not be a reasonable option; and a patient with preexisting breast asymmetry may consider bilateral mastectomy as a way to achieve symmetry and better cosmesis,” he said in an interview. “Our objective from the inception of the study, even before analyzing the results, was that this information could be part of a patient-physician discussion, never the main factor in the decision-making process.”

The authors and Dr. Boughey reported no conflicts of interest.

pwendling@frontlinemedcom.com

Pages

Recommended Reading

Endocrine therapy in metastatic breast cancer: a closer look at the current clinical practice
MDedge Hematology and Oncology
Menopause status could guide breast cancer screening interval
MDedge Hematology and Oncology
American Cancer Society recommends annual mammography starting at age 45
MDedge Hematology and Oncology
Delayed diagnosis tops breast cancer malpractice claims
MDedge Hematology and Oncology
Prolonged zoledronic acid-induced hypocalcemia in hypercalcemia of malignancy
MDedge Hematology and Oncology
Study finds no link between thyroid autoimmunity, breast cancer outcomes
MDedge Hematology and Oncology
Managing menopausal symptoms after risk-reducing salpingo-oophorectomy
MDedge Hematology and Oncology
Gene mutations had little impact on everolimus benefit in advanced breast cancer
MDedge Hematology and Oncology
Partial breast irradiation valid option to prevent local recurrence
MDedge Hematology and Oncology
Adjuvant Systemic Therapy for Early-Stage Breast Cancer
MDedge Hematology and Oncology